Shares of Novo Nordisk A/S (NYSE: NVO) dropped 1.9%today, closing at $48.25, just a whisker above the 52-week low of $45.05.

People with colon cancer who took GLP-1 drugs were less likely to die within 5 years than people not on GLP-1s, a new study ...

Novo Nordisk A/S remains attractive with strong cash flow and robust pipeline. Click here to read why NVO stock is a Buy.

Newly-elected chairman of Wegovy-maker Novo Nordisk , Lars Rebien Sorensen, said on Friday he plans to enhance the board's ...

Mice with the same genetic variant that contributes towards red hair in people were slower to recover from wounds than their black-haired counterparts ...

The study found that the five-year mortality rate was significantly lower among patients who were using GLP-1 receptor ...

Eli Lilly and Novo Nordisk’s competition in weight-loss drugs has affected thousands of jobs between Charlotte and Raleigh. Who is winning?

The executive who brought Novo Nordisk A/S’s first weight-loss shot to market is coming back as chairman of the Danish ...

The boardroom shake-up, which erupted when Novo's board Chair Helge Lund and the independent members stepped down last month ...

This episode of Pharma Pulse discusses how the FDA’s new plausible mechanism pathway, WeightWatchers’ plans to offer oral Wegovy, and emerging evidence on berberine are shaping the future of obesity ...

Obesity is one of the biggest barriers preventing patients with end-stage kidney disease from receiving a life-saving kidney ...

Why Am I Not Losing Weight on Wegovy®? How to Get Results Key takeaways: Not losing weight on Wegovy® could be due to dose, ...